Compare IDEXX Laboratories, Inc. (IDXX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TORM plc — how do they compare? IDEXX Laboratories, Inc. trades at $571.52 (market cap $46.22B), while TORM plc trades at $28.85 (market cap $2.93B). The key difference: IDEXX Laboratories, Inc. is far larger — about 15.8× TORM plc's market cap, and TORM plc pays a 9.77% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TRMD | |
|---|---|---|
Market Cap | $46.22B | $2.93B |
Sector | Health | Technology |
52-Week High | $766.68 | $34.87 |
52-Week Low | $526.44 | $18.77 |
Enterprise Value | $47.12B | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
TRMD trades at $28.84, down 1.2% with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $1.34B revenue, $285.3M net income, and a 24.41% net margin. Recent earnings show mixed performance with Q2 2026 expectations at $3.41 EPS. Analyst consensus remains unanimously bullish with 3 buy ratings. Technical indicators show oversold conditions with RSI at 24.63, while support levels cluster around $28.
The stock presents a value opportunity with attractive valuation multiples (P/E 8.4, EV/EBITDA 5.95) and strong profitability metrics (ROE 15.62%). Near-term catalysts include Q2 2026 earnings and the $0.70 dividend payment in June. Key risks include earnings volatility, tanker market cyclicality, and negative cash flow trends. Institutional ownership stability and positive analyst coverage support the bullish case despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
